None
Quote | INmune Bio Inc. (NYSE:INMB)
Last: | $ |
---|---|
Change Percent: | 3.27% |
Open: | $5.00 |
Close: | $5.05 |
High: | $5.30 |
Low: | $4.8001 |
Volume: | 22,030 |
Last Trade Date Time: | 02/12/2020 04:40:27 pm |
News | INmune Bio Inc. (NYSE:INMB)
2024-07-05 09:57:38 ET Summary INmune Bio focuses on late-stage therapy for Alzheimer's disease and natural killer cell therapy. XPro is the main focus for Alzheimer's disease, showing promising results with ongoing phase 2 study. Financially, INMB faces cash challenges but co...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...
Message Board Posts | INmune Bio Inc. (NYSE:INMB)
Subject | By | Source | When |
---|---|---|---|
Did the trial in ovarian ever start? | jondoeuk | investorshub | 04/11/2023 7:45:58 PM |
Don't need to convince us. We are fully | derkampfer | investorshub | 04/09/2023 1:10:54 PM |
Sure, it is early days in patients, but | jondoeuk | investorshub | 04/06/2023 11:10:04 PM |
blocked | dennisdave | investorshub | 12/01/2022 3:05:20 PM |
INMB chart....finally a reversal? | conix | investorshub | 03/30/2022 1:11:42 AM |
News, Short Squeeze, Breakout and More Instantly...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...
2024-06-12 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual r...